Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC

Exclusion Criteria

• •Pregnant or lactating women
• •Women of child-bearing age unable or unwilling to take effective contraceptive measures
• •Active CNS disease, brain metastases, or leptomeningeal involvement
• •Symptomatic neuropathy \> grade1 according to the NCI CTCAE (version 3.0)
• •Cardiovascular disease (class II-IV NYHA congestive heart failure, myocardial infarction within the previous 4 months, LVEF \< normal, uncontrolled hypertension, ventricular arrhythmia), anticoagulation treatment or thrombotic event within the previous 6 months
• •Active infection, requiring IV antibiotic treatment, within the previous 2 weeks
• •Long-term oxygen therapy
• •Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer
• •Radiotherapy within the previous 4 weeks
• •Previous radiotherapy to the only measurable lesion
• •Concurrent treatment with other anti-cancer drug
• •Uncontrolled hypercalcemia
• •Known allergy to drugs with similar chemical structure to study drugs. Concurrent corticosteroids, except for chronic therapy with methylprednisolone ≤ 20 mgr daily (or equivalent) for more than one month